The future of drug discovery is at Envisagenics

We use Artificial Intelligence and Machine Learning to unlock the therapeutic potential of RNA.

Our platform leverages RNA sequencing data and AI/ML algorithms to identify, test and validate drug targets with greater speed and precision than traditional methods.

Know more

Envisagenics’ SpliceCore^® software platform discovers novel targets to develop successful therapies

Traditional methods to detect RNA splicing variation have been limited – Envisagenics’ SpliceCore^® platform is able to scale the discovery of splicing-derived drug targets.

SpliceCore^® not only identifies new targets for RNA therapeutics but also explains the mechanism by which the antisense drugs regulate the splicing event, leading to more transparent and verifiable AI/ML predictions.

SpliceIO^TM, the immunotherapeutic branch of SpliceCore^®, identifies tumor specific neoepitopes targetable with a variety of antibody-based modalities.

SpliceCore^® Benchmarks

250x

larger search space for target discovery with SpliceCore’s exon-centric approach

78%

experimental validation rate for SpliceCore-discovered targets

100%

drug target candidates derived from disease-specific splicing events

View our pipeline

Oxford Global – Biologics Analysis – Insight Article – The Black Box Effect – How Can AI and ML Provide Transparent Insights for Drug Discovery?

August 30, 2022

The future of drug discovery is at Envisagenics

Envisagenics’ SpliceCore^® software platform discovers novel targets to develop successful therapies

SpliceCore^® Benchmarks

News

Envisagenics, Cancer Research Horizons, and Queen Mary University of London Announce Strategic Collaboration Agreement

Envisagenics Announces Research Collaboration with Bristol Myers Squibb

Oxford Global – Biologics Analysis – Insight Article – The Black Box Effect – How Can AI and ML Provide Transparent Insights for Drug Discovery?

Investors

Partners

Member

Foundations

The future of drug discovery is at Envisagenics

Envisagenics’ SpliceCore® software platform discovers novel targets to develop successful therapies

SpliceCore® Benchmarks

News

Investors

Partners

Member

Foundations

Envisagenics’ SpliceCore^® software platform discovers novel targets to develop successful therapies

SpliceCore^® Benchmarks